Westborough, MA, United States of America

Monir Ejemel

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of Massachusetts. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Monir Ejemel. Retrieved from https://idiyas.com/inventor/monir-ejemel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Monir Ejemel: Innovator in Gene Therapy

Introduction

Monir Ejemel is a notable inventor based in Westborough, MA (US). He has made significant contributions to the field of gene therapy and protein expression. His work is particularly relevant in the context of advancing medical treatments and biotechnological applications.

Latest Patents

Monir Ejemel holds a patent for "Synthetic Promoters for Gene Therapy and Protein Expression." This innovative patent reflects his commitment to enhancing the efficacy of gene therapy techniques. With 1 patent to his name, Ejemel's work is paving the way for future advancements in the field.

Career Highlights

Ejemel is affiliated with the University of Massachusetts, where he continues to engage in research and development. His role at the university allows him to collaborate with other experts and contribute to groundbreaking projects in biotechnology.

Conclusion

Monir Ejemel's contributions to gene therapy and protein expression exemplify the impact of innovative thinking in science. His patent and ongoing work at the University of Massachusetts highlight his dedication to advancing medical technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…